An interventional study of Right Greater Splanchnic Nerve (GSN) ablation and Sham Control in Heart Failure With Reduced Ejection Fraction (HFrEF), sponsored by Axon Therapies, Inc.. Recruiting at 9 sites in 5 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Axon Therapies, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 342 studies in Heart Failure with a site in Spain — 76 open to participants now, 99 under way, 21 of them phase 3. Heart Failure · Spain.
Among the 342 studies in Heart Failure with a site in Spain, this one is the 235th largest by planned enrollment of the 263 interventional ones that give a count, is one of 22 that started in 2026, is one of 119 with no phase, reaches primary completion later than 66 of the 98 other live ones, and was the 327th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →76 of the 342 studies in Heart Failure with a site in Spain are open now. Recruiting first, the newest first:
AnaCardio AB · Sites in Spain, United States, Bulgaria and 5 more countries
Ages 18–85
Carolina Ortiz Cortes · Sites in Spain
Ages 18+ · Women only
AstraZeneca · Sites in Spain, United States, Argentina and 29 more countries
Ages 18+
AstraZeneca · Sites in Spain, United States, Germany and 2 more countries
Ages 18+
Biotronik SE & Co. KG · Sites in Spain, Austria, Czechia and 4 more countries
Ages 18–99
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
342 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 42 · Phase 3 78 · Phase 4 24
First in 1983; this study’s year is marked. 22 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 294 across the 263 interventional studies, 500 across the 78 observational. Of the 213 that completed or were terminated, 86 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
190 of 342 have an industry lead sponsor. The 10 most frequent:
Axon Therapies, Inc. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Axon Therapies, Inc. has 3 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
31 of the studies in Heart Failure with a site in Spain that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07008365Phase 3Instituto de Investigación Sanitaria AragónThe Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure | 2026-11-30 |
| NCT06578078Phase 3Fundación para la Investigación del Hospital Clínico de ValenciaA Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients | 2026-12-30 |
| NCT06712030Phase 3Puerta de Hierro University HospitalEffect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction | 2027-04 |
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
Add all 31 to your calendar (.ics) → With an account.
Among the 342 studies in Heart Failure with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a small, early-stage clinical trial designed to test whether a new catheter-based procedure is safe and may help people with heart failure with reduced ejection fraction (HFrEF). The procedure uses the Satera Ablation System to treat the right greater splanchnic nerve, which may play a role in heart failure symptoms. The study also aims to identify which types of patients might benefit most from this treatment in the future.
Up to 50 patients aged 40 or older with HFrEF will take part at as many as 10 hospitals worldwide. The study is prospective, meaning patients are followed forward in time, and it is randomized, double-blinded, and sham-controlled. Patients are randomly assigned in a 2:1 ratio to either receive the actual nerve ablation treatment or a sham (placebo) procedure. Randomization happens during the procedure, after anesthesia or sedation, to reduce the risk of revealing which treatment the patient receives.
Neither the patient nor their heart failure doctor will know whether the patient received the real treatment or the sham. However, the doctor performing the procedure and certain study staff will know, mainly for safety and operational reasons.
The sham procedure is designed to mimic the real procedure as closely as possible without performing the nerve ablation. It involves placing a small needle in the groin or neck and accessing the vein, but no treatment catheter is inserted. The sham procedure takes about the same amount of time as the real treatment (around 45 minutes) to help account for any placebo effect.
Overall, this study is focused on evaluating safety and early signs of benefit rather than proving long-term effectiveness.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Chronic heart failure, defined as:
Ongoing stable GDMT HF management for a minimum of 30 days prior to screening (unless unable to tolerate GDMT) which refers to those HF drugs carrying a Class I indication, including:
Exclusion Criteria:
Advanced heart failure defined as one or more of the following:
Presence of significant valve disease defined by the site cardiologist as:
Estimated peak pulmonary artery pressure (PAP) > 70 mmHg (at screening visit and determined by echo core lab).
Exclusion Criteria Assessed During the index procedure:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects receive catheter-based unilateral ablation of the right greater splanchnic nerve (GSN) using the Satera Ablation System. Randomization occurs during the procedure after anesthesia or sedation and after confirmation that the subject's vein anatomy is suitable for treatment.
Device: Right Greater Splanchnic Nerve (GSN) ablation
Subjects undergo a simulated procedure designed to mimic the treatment experience without delivering nerve ablation. This includes venous access via a small needle puncture in the groin or neck and assessment of vein anatomy, but no treatment catheter is inserted and no ablation is performed. The sham procedure lasts approximately the same amount of time as the active treatment.
Procedure: Sham Control
Subjects receive catheter-based unilateral ablation of the right greater splanchnic nerve.
Simulated procedure designed to mimic the treatment experience without delivering nerve ablation
Device or procedure related serious adverse events
Evaluation of device or procedure related serious adverse events based on Clinical Events Committee (CEC) assessment
Time frame: Treatment through the 1 month
NT-proBNP (6 months)
Assessment of change in NT-ProBNP from baseline to 6-month follow up visit
Time frame: Baseline through the 6 months
Serious device related cardiac or vascular events
Incidence of serious device related cardiac or vascular events for up to 12 months
Time frame: Treatment through the 12 months
Device or procedure related pain
Device or procedure related pain lasting at least 30 days and requiring medical management
Time frame: Enrollment through the 12 months
Orthostatic hypotension
Incidence of new orthostatic hypotension up to 12 months
Time frame: Procedure through 12 months
Acute Kidney Injury
Incidence of AKI requiring renal replacement therapy up to 12 months
Time frame: Procedure through 12 months
Worsening Glomerular Filtration Rate (GFR)
Incidence of worsening GFR (defined as change \> 50% for at least 30 days in duration) up to 12 months
Time frame: Procedure through 12 months
Adverse Events
Incidence of all Adverse Events through 12 months
Time frame: Procedure through 12 months
Mortality
Incidence of all mortality for up to 12 months summarized as all-cause mortality, CV mortality, or heart failure-related
Time frame: Procedure through 12 months
Left Ventricular End Diastolic Volume (LVEDV)
Change in LVEDV from baseline indexed for body surface area (LVEDVi ml/m2) at 6 and 12 month follow up
Time frame: Baseline through 6- and 12- months
Left Ventricular Ejection Fraction (LVEF)
Change in LVEF from baseline at 6 and 12 month follow up
Time frame: Baseline through 6- and 12-months
NT-proBNP (12 months)
Change in NT-proBNP evaluated over time from baseline through 12 months
Time frame: Baseline through 12 months
Kansas City Cardiomyopathy Questionnaire (KCCQ)
Change in KCCQ scores evaluated over time from baseline through 6 and 12 months
Time frame: Baseline through 6- and 12-months
6-minute Walk Test (6MWT)
Change in 6MWT evaluated over time from baseline through 6 and 12 months
Time frame: Baseline through 6- and 12-months
Worsening Heart Failure (Time to)
Time to first heart failure hospitalization or worsening heart failure event through 6 and 12 months
Time frame: Baseline through 6- and 12-months
Worsening Heart Failure (Incidence)
Incidence of heart failure hospitalization and worsening heart failure events through 6 and 12 months
Time frame: Baseline through 6- and 12-months
Composite Endpoint
Hierarchical composite endpoint of cardiovascular death, heart failure events, and changes from baseline to 12 months in KCCQ OSS
Time frame: Baseline through 12 months
Diuretic Dose
Change in diuretic dose through 6 and 12 months
Time frame: Baseline through 6- and 12 months
High Sensitivity C-reactive Protein
Change in high sensitivity C-reactive protein levels from baseline through 6 and 12 months
Time frame: Baseline through 6- and 12 months
Weight
Change in weight from baseline through 6 and 12 months
Time frame: Baseline through 6- and 12 months
HbA1c
Change in HbA1c from baseline through 6 and 12 months
Time frame: Baseline through 6- and 12 months
Technical Success (Primary) - treatment cohort only
Technical success of RF ablation of the GSN at the T11 level, defined as successful catheter positioning at the target site, completion of RF energy delivery, and absence of device-related Serious Adverse Events.
Time frame: Procedure
Technical Success (Secondary) - treatment cohort only
Technical success (Secondary) of RF ablation of the GSN at the T10 level, defined as successful catheter positioning at the target site, completion of RF energy delivery, and absence of device-related Serious Adverse Events.
Time frame: Procedure
SGLT2 Inhibitor Dose
Number of changes in SGLT2 Inhibitor dose and percentage of subjects with at least one change through 6- and 12-months
Time frame: Baseline through 6- and 12-months
Angiotensin Receptor Blocker (ARB) Dose
Number of changes in Angiotensin Receptor Blocker Dose and percentage of subjects with at least one change though 6- and 12-months
Time frame: Baseline through 6- and 12-months
ACE Inhibitor Dose
Number of subjects with changes in ACE Inhibitor Dose and percentage of subjects with at least one change through 6- and 12-months
Time frame: Baseline through 6- and 12-months
Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Dose
Number of subjects with changes in Angiotensin Receptor-Neprilysin Inhibitor dose and percentage of subjects with at least one change through 6- and 12-months
Time frame: Baseline through 6- and 12-months
Aldosterone Antagonist (MRA) Dose
Number of subjects with changes in Aldosterone Antagonist (MRA) Dose and percentage of subjects with at least one change through 6- and 12-months
Time frame: Baseline through 6- and 12-months
Beta Blocker Dose
Number of subjects with changes in Beta Blocker dose and percentage of subjects with at least one change through 6- and 12-months
Time frame: Baseline through 6- and 12-months
Aldosterone (ALD)
Change in aldosterone levels from baseline through 6- and 12-months
Time frame: Baseline through 6- and 12-months
Renin
Change in Renin levels from Baseline through 6- and 12-months
Time frame: Baseline through 6- and 12-months
Plan to share: Undecided
Started Jun 2026 (actual). Primary completion is estimated for Mar 2028, 20 months after the start.
Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 20 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
Start moved once since we started tracking on Sep 25, 2026: Mar 2026 → Jun 2026, on Nov 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.